November 24, 2015
Lilly’s lung cancer drug in combo with gemcitabine and cisplatin gets FDA’s OK
Eli Lilly has gotten the U.S. Food and Drug Administration (FDA) approval for cancer drug Portrazza, which comes in a form of injection for intravenous use, 800 mg/50 mL, in combination with gemcitabine and cisplatin.